Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis fluid removal trial aims to ease heart strain

NCT ID NCT07637110

Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding extra ultrafiltration (a gentle fluid-removal procedure) for 4 or 8 weeks can safely reduce excess fluid in people on hemodialysis. The goal is to lower high blood pressure and relieve symptoms like congestion. About 120 adults with end-stage kidney disease and signs of fluid overload will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrafiltration (a gentle fluid-removal procedure during dialysis)
What this could lead to
If successful, this could offer a simple way to reduce high blood pressure and fluid-related symptoms in dialysis patients, potentially lowering hospitalizations.
What could go wrong
This is a small, early-stage trial with only 120 participants. The extra fluid removal may cause side effects like low blood pressure or cramps, and benefits may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either: 1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered. OR 2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \<75. Exclusion Criteria: * Age \<18 years * Receiving hemodialysis treatments for acute kidney injury * Receiving hemodialysis treatments for less than four weeks * Planned switch to peritoneal or home dialysis within next three months * Current or planned incremental hemodialysis (less than 3 treatments per week) * Current or planned intensive hemodialysis (four or more treatments per week) * Scheduled kidney transplantation * Major cardiovascular or bleeding event within previous 90 days * Receiving chemotherapy or radiation treatment for cancer * History of cirrhosis with ascites * Inability to complete 24-hour ambulatory blood pressure measurement * Wheelchair dependance or other inability to complete six-minute walk test * Pre-dialysis systolic blood pressure \<100 mmHg * Scheduled use of midodrine with hemodialysis treatments * History of non-adherence with dialysis treatments * Pregnancy * Institutionalized * Current or pending enrollment in hospice care * Inappropriate for enrollment based on investigator or nephrologist discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease Edema end stage renal failure hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood pressure management End-stage renal disease (ESRD) Fluid accumulation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwest Kidney Centers

    Seattle, Washington, 98112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.